Blick ins Buch

Bortezomib in the Treatment of Multiple Myeloma

Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson (Herausgeber)

Buch | Hardcover

VIII, 180 Seiten

2010 | 2011
Springer Basel (Verlag)
978-3-7643-8947-5 (ISBN)

Lese- und Medienproben

Blick ins Buch (midvox)

Artikel merken

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

Erscheint lt. Verlag	11.11.2010
Reihe/Serie	Milestones in Drug Therapy
Zusatzinfo	VIII, 180 p.
Verlagsort	Basel
Sprache	englisch
Maße	155 x 235 mm
Gewicht	439 g
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
	Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
	Naturwissenschaften ► Biologie ► Zellbiologie
Schlagworte	Apoptosis • Bortezomib • Cancer Therapy • multiple myeloma • Myelom • Oncology • pharmacology • Proteasome inhibitors • Velcade
ISBN-10	3-7643-8947-8 / 3764389478
ISBN-13	978-3-7643-8947-5 / 9783764389475
Zustand	Neuware